All In Biotech

Drug Trial Radar · NCT02787278

Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPA

A Prospective, Randomized, Double-blinded Phase IIa Clinical Trial to Investigate the Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPA Standard of Care

Last checked: Nov 20, 2026Latest source record: Jul 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Jun 5, 2016

Primary completion

May 30, 2017

Study completion Aug 22, 2017

Sponsor

Sponsor type
Industry
First posted
Jun 1, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 19 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The current study aims to evaluate the safety of SP-8203, designing in two stages (stage-1, stage-2) to evaluate the safety and efficacy of the combination therapy of SP-8203 and rtPA for the occurrence of cerebral hemorrhage in patients with acute ischemic stroke receiving rtPA standard of care.

Conditions

  • Ischemic Stroke

Interventions

  • SP-8203 High doseDrug

    High-dose group: 160mg will be intravenously administered as 80mg/dose twice daily (intervals of 12 hours).

  • SP-8203 Low doseDrug

    Low dose group: 80mg will be intravenously administered as 40mg/dose twice daily (intervals of 12 hours).

  • PlaceboDrug

    Same dosage of SP8203. Placebo will be intravenously administered twice daily (intervals of 12 hours)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The ratio of the incidence of parenchymal hematoma observed on brain CTTime frame: Brain CT should be performed at 24 ± 3 hours after the complete administration of the first dose of IP. (Screening, Baseline ,Day 0, Day 1)

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Pusan National University Hospital

    Busan, South Korea

  • Kyungpook National University Hospital

    Daegu, South Korea

  • Myongji Hospital

    Gyeonggi-do, South Korea

  • Inje University Busan Paik Hospital

    Pusan, South Korea

  • Asan Medical Center, University of Ulsan

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • KyungHee University Medical Center

    Seoul, South Korea

  • Soonchunhyang University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.